Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Long-Term Extension in Crohn's Disease
NCT02513459Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Sep 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02513459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513459.